The initial success of Sildenafil undeniably reshaped the pharmaceutical landscape, but investing in companies primarily reliant on off-patent versions presents a challenging picture. While early profits were substantial, the cessation of patents and the rise of less expensive alternatives have eroded sales. Consequently, a thorough evaluation of c